Government of India

Department of Pharmaceuticals

Ministry of Chemicals & Fertilizers

Shastri Bhawan, New Delhi

India Pharma and India Medical Devices Awards Guidelines

with

Criteria/Indicators for 7th India Pharma and India Medical Device Awards

(as on March, 2022)

CODE OF PROCEDURE

CONTENTS

Section-I: Introduction

1. Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian Pharma ranks third in pharmaceutical production by volume. In the last nine years, Indian Pharma sector has grown steadily by CAGR of 9.43%. Pharma sector has been consistently earning trade surplus. During 2020-21, total pharma export was ₹180555 crore (USD 24.35 Bn) against the total pharma import of ₹49436 crore (USD 6.66 Bn), thereby generating trade surplus of USD 17.68 Bn. Till end September 2021 total pharma export has been ₹ 87864 crore (USD 11.88 Bn) as against total import of ₹ 33636 crore (USD 4.66 Bn), thereby generating a trade surplus of ₹ 54228 crore (USD 7.22 Bn). Major segments of Indian Pharmaceutical Industry include generic drugs, OTC medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilars and biologics.

2. Indian pharmaceutical industry also plays significant role globally. India has the highest number of United States Food and Drug Administration (USFDA) compliant Pharma plants outside of USA. There are 500 API manufacturers contributing about 8% in the global API Industry. India is the largest supplier of generic medicines with 20% share in the global supply by manufacturing 60000 different generic brands across 60 therapeutic categories. Access to affordable HIV treatment from India is one of the greatest success stories in medicine. India is one of the biggest suppliers of low-cost vaccines in the world. Because of the low price and high quality, Indian medicines are preferred worldwide, thereby rightly making the country the “pharmacy of the world”.

3. The Indian pharma industry has also played an important role in meeting the challenges for mitigation of the infection in COVID pandemic. The industry worked in close collaboration with the government and academic institutes etc., to quickly develop and refine manufacturing processes which helped to ensure a consistent supply of medicines needed for the management of COVID-19 (e.g., Remdesivir, Ivermectin, Hydroxychloroquine, Dexamethasone, Tocilizumab, Favipiravir etc.). Indian drug supplies throughout the COVID-19 pandemic period have provided relief to over 120 countries for Hydroxychloroquine (HCQ), 20 countries for paracetamol and about 96 countries for vaccines across the world.

4. Major Credentials of Pharma Industry
   - India provides generic medicines to more than 200 countries
   - 8 out of 20 Global Generic companies are from India
   - Over 55% Exports to Highly Regulated Markets
   - 90% of WHO Pre-Qualified APIs are sourced from India
   - 65-70% of WHO’s vaccine requirements are sourced from India

- No. of USFDA approved sites: 725 (as of June 2021)
- No. of ANDA Market Authorizations secured by Indian companies: 4,346 (as on December 2020)

5. Medical Device industry is a sunrise sector and has the potential of growing highest among all the sectors in the healthcare system. Various categories of devices starting from consumables to implantable medical devices are being manufactured in India. Major manufacturing of medical devices in the country is happening with respect to disposables such as catheters, perfusion sets, extension lines, cannula, feeding tubes, needles, syringes, and implants such as cardiac stents, drug-eluting stents, intra-ocular lenses and orthopedic implants.

6. The Medical Device industry is highly capital intensive with a long gestation period and requires development/induction of new technologies. The sector also requires continuous training of healthcare system providers to adapt to new technologies. Most of the high technology and innovative products originate from a well-developed ecosystem and innovation cycle, which is yet to be fully developed in India. India depends on imports to an extent of 85% of its domestic requirements of medical devices.

7. India is one of the fastest growing markets in the global medical devices industry and is expected to grow at a CAGR of 15 per cent. Indian medical devices market stood at USD 11 billion in 2020. Indian Medical Device industry is expected to reach USD 50 Bn by 2030. India is the 4th largest Asian medical devices market after Japan, China, and South Korea and among the top 20 global medical devices markets in the world. Currently, India is exporting ventilators, PPEs, diagnostic kits, sanitizers and surgical gloves (2/3 ply) etc.

8. The vision of the Department is to promote Indian pharma as the global leader for quality medicines and to ensure availability, accessibility and affordability of drugs and medical devices in the country.

9. The Mission of the Department are as follows:

    - Investment for Make in India in pharma sector,
    - Make in India in critical APIs and medical devices,
    - Industry expansion, skilling, R&D and innovation,
    - Stable and effective price regulation and
    - Generic medicines by expanding Janaushadhi scheme

10. India is well recognized as the pharmacy of the world. The pharmaceutical industry has played a key role in driving better health outcomes across the world by being a large and reliable supplier of affordable and high-quality generics drugs. Increased accessibility to affordable drugs in India has helped reduce disease burden in the country by 36 percent between 1990 and 2016 and has also brought down treatment cost for several life-threatening diseases to <5% of its original cost. India has also helped improve access globally by supplying ~60% of global vaccine supply, 20-22% of generic exports, enabling access to AIDS treatment to 37% of patients in Africa in 2009 compared to just 2% in

2003 and by being the 2nd largest exporter of Ayurveda and alternative medicine in the world. The industry has also contributed significantly to India's economy by providing employment to 2.7 Mn people, generating USD 13 Bn in trade surplus every year, and USD 2 Bn in FDI inflows to pharmaceutical industry in the period 2015 to 2018. The focus on high quality is borne out by the presence of largest number of USFDA accredited manufacturing plants outside of the US. Indian pharmaceutical industry's contribution has become even more prominent in 2020 as India has supported the global battle against COVID-19 pandemic by maintaining drug supplies to about 200 countries even during the darkest days of the pandemic.

11. While giving a clarion call for 'Atmanirbhar Bharat', the Hon'ble Prime Minister highlighted that India can only achieve self-reliance in pharmaceuticals and medical devices by strengthening its R&D infrastructure that would drive expansion of access to life-saving medicines and help India become a global pharmaceuticals and medical devices exports hub. Also, the Parliamentary Standing Committee in its 46th Report on 'Promotion and coordination of basic, applied and other research in areas related to the Pharmaceutical Sector' in July, 2018 recommended for institutionalizing inter-departmental coordination mechanism, enhancing academia-industry linkage, boosting infrastructure, enhancing budget allocation for Pharmaceuticals and medical devices Research & Development, concentrating on future areas of research, like biologics and re-adjusting policy, rules & regulations. In pursuance to the recommendations of the Committee, an Inter Departmental Committee (IDC) was set up by the Department of Pharmaceuticals in January, 2019 to institutionalize a robust mechanism to ensure efficiency, effectiveness and transparency and coordinate research in a collaborative, synchronized and synergized way for optimum utilization of funds and to ensure no overlapping and duplication of efforts and resources.

12. More recently, the challenges faced in India and indeed globally during the pandemic years of 2020 and 2021 have generated insights that growth must also serve the aims to assure drug security, diversify supply chains, increase access and develop innovative solutions to meet health care needs at scale. Whereas other support, in the form of regulation for safety and quality, financing, manufacturing infrastructure, skilled manpower, and cross border cooperation will no doubt be necessary for achieving these multiple objectives, Innovation and Research will be important contributors for sustaining them.

13. Several enablers including a strong local industry, export experience, and depth of technical capabilities can help Pharma and Medtech sectors work towards the vision of "Discover in India" and build a strong ecosystem for healthcare innovation. Achieving this vision will not only help India maintain its global relevance but also drive several health and economic benefits for the country. India although well placed in generics and certain medical devices, is yet to demonstrate sustained higher capabilities relating to drug discovery in pharmaceuticals, new products in biopharma and high-end medical devices.

Building this presence can generate substantial health benefit for India by enabling development of drugs for India-specific ailments, which do not get adequate attention globally (e.g., drug-resistant infections like NDM-1; oral cavity cancer, where India accounts for ~30% of diseases burden). It will also enhance industry's contribution to India's economy (additional USD 10-12 Bn in exports every year) and create large pool of white-collar jobs to enhance India's differentiation vis a vis other developing economy.

Section–II: Definitions

1. **Applicant:** Applicant for the purpose of the India-Pharma Award shall be any Proprietary Firm or Partnership Firm or Limited Liability Partnership (LLP) or Startup or MSME or a Company registered in India proposing to manufacture of Pharmaceuticals, Bio-Pharma and Medical Devices products. The applicant shall make an online application.

2. **Formulation**: A finished dosage form, for example tablet, capsule, solution, injectable, ointment, semisolid, etc. that contains an active drug ingredient along with other ingredients. **Biopharmaceuticals will also be covered under Pharma Category**.

3. **Active Pharmaceutical Ingredient (API):** Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure or function of the body.

4. **Medical Devices,** as defined in the Medical Devices Rules 2017 read with Drug and Cosmetics Act, 1940 and rules thereon.

5. **Manufacturing:** In accordance with Central Goods and Services Tax (CGST) Act, 2017, manufacturing shall mean processing of raw material or inputs in any manner that results in emergence of a new product having a distinct name, character and use and the term "manufacturer" shall be construed accordingly.

6. **MSME:** Applicants registered as Micro, Small & Medium Enterprises (MSME) with the Ministry of MSME, Government of India.

7. **Start-up:** Applicants registered as Start-up under DPIIT, Ministry of Commerce, Government of India.

Section–III: India-Pharma and Medical Devices Awards Scheme

1. The Pharmaceuticals and Medical Devices sector is a key sector of the global (and Indian) economy. At the same time, India can only achieve self-reliance in pharmaceuticals and medical devices by strengthening its R&D infrastructure that would drive expansion of access to life-saving medicines and help India become a global pharmaceuticals and medical devices exports hub. This concern needs to be addressed by being at the forefront

of R&D and technology development in this sector as also to enhance the pace of innovation in this field. This on the one hand, would create pressures that would motivate companies to innovate and on the other hand, the scale up the production with quality will guide sustainable product and process interventions. With the above-mentioned objectives, Government of India, Department of Pharmaceuticals has decided to set up an Award Scheme to recognize and reward valuable contributions, motivate, encourage innovations and inventions in the field of Pharmaceuticals, Bio-Pharma and Medical Devices, products, processes and other areas of national and social importance respectively. The various applications of Pharmaceuticals, Bio-Pharma and Medical Devices have already penetrated in all walks of life including various manufacturing sectors by participating in the Scheme PLI Bulk Drug, PLI Medical Devices and PLI Scheme of Pharmaceuticals

2. This India-Pharma award scheme will motivate the inventors to carry out innovative Research & Development in the areas of Pharmaceuticals, Bio-Pharma, Medical Devices and allied industry, which in turn will improve performance / quality of the existing product. This award will be on outstanding contribution in Protocol and Non-protocol COVID-19 drug and Medical Devices Manufacturing, R&D investment, Revenue generation, Exports, Number of APIs related to COVID, Startups in respect of New Biological Entities and New Chemical Entities, Biologics, Imaging medical technologies, New Materials, tele-diagnostics, AI/ML based innovations, Sensors, etc. NPPA will be supported to develop greater expertise in pricing of new innovative products, while pursuing affordability as an overall objective of innovative new products, quality standards, recycling and other emerging areas.

3. These awards are also intended to enhance innovative capacities to a level of international recognition. The ultimate objective is to develop and maintain the Pharmaceuticals, Bio-Pharma, Medical Devices industry as a globally competitive industry using eco-friendly processes & technologies. This scheme will help improve the performance of the existing product and its quality leading to better acceptance and increase in demand of the product in the competitive market of Pharma and Medical Devices. This will benefit both small and medium enterprises as well as larger companies. Applicant has to apply online for award under any category/sub-category as per prescribed applicable formats separately for Leaders Category /Company /MSME / Start-up /Innovation / CSR (Annexures attached).

Section–IV: Eligibility for the awards

1. The awards are open to all Pharmaceuticals/Bio-Pharma/Medical Devices companies and domestic manufacturers / Start-up registered in India or created by the Central/ State governments/ Union Territories.

2. **In case of a team or group, the maximum number of the applicants in a team/group in any particular Prize Award Application should not be more than three**.

3. The innovation should either be a patent filed, product patents granted original product, commercialized patent products related to COVID management, commercialized patent products related to NLEMs process or an improvement on existing product or process so as to increase utility of the product or process by enhancing consumer advantages, accuracy, reliability, safety, product life, versatility, etc. Mere theoretical hypothesis, innovation simply in the idea stage and perpetual motion machines are not eligible for consideration of an award.

4. The innovation **should be not older than three years**, at the time of submitting the application.

5. To promote new innovators/ researchers/ scientists and to bring them forward with their innovations, awardees of previous editions of the India-Pharma Awards will be deemed ineligible to participate in the India-Pharma Awards for the next two editions/years.

Section-V: Periodicity of the awards

1. The awards shall be conferred annually.
2. If, however, it is considered that none of the recommendations merit recognition, no award shall be given in the category.

Section-VI: Implementation Framework & Operational Modalities

1. The entry applications for awards will be screened and evaluated by the Expert Committee. The members of the Expert Committee will be nominated by the Department and would be headed by a renowned scientist/ expert of the domain nominated by the Department.

2. Evaluations report of the Expert Committee will be placed before the Prize Award Committee, which would be chaired by Joint Secretary (Scheme). The Prize Award Committee will have representation from National Level Academic Institutions / Research Laboratories, National Level Industry Associations, Expert Committee and representatives from Government of India. **The names recommended by Expert Committee may be asked to present their innovation/project etc. before the Prize Award Committee**. Prize Award Committee would then submit its recommendations on awardees for final approval of Secretary (Pharma).

3. The India-Pharma Awards will be **organised by the Department in coordination with the Industry Associations.**

4. The non-official members of the Committees shall be entitled to travelling and daily

allowance in accordance with the Financial Rules and procedures as applicable in the Government of India.

5. The award and its categories may change as per the need of the hour with recommendation of Expert Committee.

Section–VII: Presentation of the awards

1. The awards, as far as possible, shall be presented at New Delhi at a special ceremony/function in the month of February/ March.

2. The awardees shall be invited to receive the awards in person. No TA/DA will be provided to awardees for attending the function.

3. Before the announcement of conferment of the awards, the concurrence of the prospective awardees shall be ascertained. However, even after giving such acceptance, if an awardee declines to accept the award, the award shall immediately revert to the Ministry.

4. The following awards shall be presented every year to an Leaders Category /Company /MSME / Start-up /Innovation / CSR for outstanding contribution in the field of Pharmaceuticals/Bio-Pharma/Medical Devices and allied sectors which has created significant impact in the country. The awards carry, a memento (as below) in each category.

Description of the awards Category	**Number of awardees**
Leaders Category	Two (2)
Company of the year	Three (2)
MSME of the year	Two (2)
Start-ups of the year	Two (2)
Innovation Category	Two (2)
CSR	One (1)
Total	**12 Awards**

Section–VIII : Criteria/Indicators for 7th India Pharma and India Medical Device Awards (to be given in April 2022)

(performance of the Pharma and Medical Devices Industries till FY 20-21)

A. Leaders Category - 2
B. Company of the year - 3
C. MSME of the year – 2
D. Start-ups of the year - 2
E. Innovation Category – 2
F. CSR category – 1

Factors for submission of applications for awards

1. Online portal to submit the applications
2. Data of FY 20-21 to be evaluated;
3. For MSME, definition under PLI scheme for Pharmaceuticals will be utilized.
4. Highest of all entries received to have full marks and others as proportionate.
5. Audited parameters such as sales, exports, R&D expenditures, duly certified by Company Secretary, to be considered.
6. List of Protocol and Non-protocol drugs (as per CDMC monitoring) proposed to be considered – if required, CDSCO's comments will be taken.
7. Medical devices / equipment for COVID management – to be confirmed by CDSCO
8. For Start-ups, those registered with the DPIIT will be considered for evaluation.
9. **Biopharmaceuticals will also be covered under Pharma Category**

A. Leaders Category Awards

1. India Pharma Leader Award

Criterion of Selection with weightage

a. Average of Sales Turn over for the last three years – **25 marks**
b. Average of the Exports Turn over for the last three years – **25 marks**
c. Average of the Sales of NLEMs vis-à-vis total sales for the last three years - **20 marks**
d. No of products – Protocol and Non-protocol COVID drugs produced for the last two FYs – **10 marks**
e. Average of the Expenditures on R&D vis-à-vis total sales turn over for the last three years – **10 marks**

2. India Medical Devices Leader Award

Criterion of Selection with weightage

a. Average of Sales Turn over for the last three years – **25 marks**
b. Average of the Exports Turn over for the last three years – **25 marks**
c. No of products – medical devices / equipment for COVID management produced for the last two FYs – **20 marks**
d. No of Medical Devices / Equipment (other than the notified MDs) already registered with the CDSCO till 31.12.2021 (during the voluntary registration period) – **20 marks**
e. Average of the Expenditures on R&D vis-à-vis total sales turn over for the last three years – **10 marks**

B. Company of the year Awards

1. India Pharma Bulk Drug company of the year

Criterion of Selection with weightage

a. % Increase in Sales Turn over vis-à-vis last year– **25 marks**
b. % of sales of APIs for manufacture of NLEM medicines– **25 marks**
c. % sales of APIs related to production of COVID drugs (Protocol and non-protocol) – **20 marks**
d. Number of APIs related to COVID management produced in FY 20-21 - **20 marks**
e. % Increase in R&D Expenditure on Bulk drugs vis-à-vis last year – **10 marks**

2. India Formulation Company of the year

Criterion of Selection with weightage

a. % Increase in Sales Turn over vis-à-vis last year– **25 marks**
b. % of sales of of NLEM medicines vis-à-vis total sales – **25 marks**
c. % sales of Medicines for COVID management (Protocol and non-protocol) – **20 marks**
d. Number of Medicines for COVID management produced in FY 20-21 - **20 marks**
e. % Increase in R&D Expenditure on formulation drugs drugs vis-à-vis last year – **10 marks**

3. India Medical Device company of the year

Criterion of Selection with weightage

a. % Increase in Sales Turn over vis-à-vis last year– **25 marks**
b. % of export out of total sales in the FY 20-21– **25 marks**
c. % of sales of Medical Devices for COVID management produced out of total sales in FY 20-21– **20 marks**
d. Number of Medical Devices for COVID management produced in FY 20-21 - **20 marks**
e. % Increase in R&D Expenditure on Medical Devices vis-à-vis last year – **10 marks**

C. MSME Category Awards

1. India Pharma / API MSME of the year

Criterion of Selection with weightage

a. % Increase in Sales Turn over vis-à-vis last year– **25 marks**
b. % of sales of of NLEM APIs / medicines vis-à-vis total sales – **25 marks**
c. % sales of APIs / Medicines for COVID management (Protocol and non-protocol) – **20 marks**
d. Number of APIs / Medicines for COVID management produced in FY 20-21 - **20 marks**
e. Financial assistance received from MSME schemes of Govt of India / State Government – **10 marks**

2. India Medical Device MSME of the year

Criterion of Selection with weightage

a. % Increase in Sales Turn over vis-à-vis last year– **30 marks**
b. % sales of Medical Devices / Equipment for COVID management (Protocol and non-protocol) – **30 marks**
c. Number of Medical Devices / Equipment for COVID management produced in FY 20-21 - **30 marks**
d. Financial assistance received from MSME schemes of Govt of India / State Government – **10 marks**

D. Start-up category

1. India Pharma Start-up of the year

Criterion of Selection with weightage

a. Cumulative number of the pharmaceutical products produced by the Start-up – **25 marks**
b. Average of the sales of the pharmaceutical products during last three years – **25 marks**
c. cumulative Number of Pharmaceutical products registered with GeM portal by Start-up firm in last three years – **20 marks**
d. Cumulative Number of Pharmaceutical products approved by CDSCO/ AERB/ Regulatory approval of USA, UK, Australia, Japan, Canada, European Union (CE) in last three years .- **20 marks**
e. Number of the new pharmaceutical products / new processes, used by the Start-up firms for the last three years – **10 marks**

2. India Medical Device Start-up of the year

Criterion of Selection with weightage

a. Cumulative number of the Medical Devices / Equipment produced by the Start-up – **25 marks**
b. Average of the sales of the Medical Devices / Equipment during last three years – **25 marks**

c. cumulative Number of Medical Devices / Equipment registered with GeM portal by Start-up firm in last three years – **20 marks**
d. Cumulative Number of Medical Devices / Equipment approved by CDSCO/ AERB/ Regulatory approval of USA, UK, Australia, Japan, Canada, European Union (CE) in last three years .- **20 marks**
e. Number of the new Medical Devices / Equipment / new processes, used by the Start-up firms for the last three years – **10 marks**

E. Innovation Category

1. India Pharma Innovation of the year

Criterion of Selection with weightage

a. Number of the patents filed for the last three years – **25 marks**
b. Number of product patents granted during the last three years - **(25 Marks)**
c. Average sales of the commercialized above patent products during the last three years – **25 marks**
d. % sales of commercialized patent products related to NLEMs – **25 marks**

2. India Medical Device Innovation of the year

Criterion of Selection with weightage

a. Number of the patents related to the medical devices filed for the last three years – **25 marks**
b. Number of product patents related to medical devices granted during the last three years - **(25 Marks)**
c. Average sales of the commercialized above patent products during the last three years – **25 marks**
d. % sales of commercialized patent products related to COVID management– **25 marks**

F. CSR Category

India Pharma CSR company of the Year Award:

Criterion of Selection with weightage

a. Total expenditure incurred on these activities for the last three years **– 20 marks**
b. % of expenditure incurred towards improvement of public system such as public healthcare system, public educational institutions, etc **– 20 marks**
c. % of expenditure incurred on skill upgradation - **– 20 marks**
d. No of Districts covered under the CSR Programme for the last three years **– 20 marks**
e. No of Aspirational Districts covered under the CSR programme for the last three years **– 20 marks**

Section–VIII: Sample Formats of Application

INDIA-PHARMA AWARDS

Annexure-A

Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Govt. of India

SAMPLE APPLICATION

1.Category of Award **:**

(An applicant can submit one Innovation in maximum of 2 Categories only (If found suitable)

- ☐ India Pharma Leader Award
- ☐ India Medical Devices Leader Award
- ☐ India Pharma Bulk Drug Company of the year
- ☐ India Formulation Company of the year
- ☐ India Medical Devices Company of the year
- ☐ India Pharma/ API MSME of the year
- ☐ India Medical Devices MSME of the year
- ☐ India Pharma Start-up of the year
- ☐ India Medical Devices Start-up of the year
- ☐ India Pharma Innovation of the year
- ☐ India Medical Devices Innovative of the year
- ☐ India Pharma CSR company of the year Award

INDIA-PHARMA AWARDS

CERTIFICATE OF UNDERTAKING

Category:

Title of Innovation:

I / We have read and fully understood the terms and conditions & the eligibility criteria and fulfill the same. I / We also understand that mere fulfillment of eligibility criteria does not entitle me / us for the award. Further, the information provided by me / us is true and correct to the best of my / our knowledge and beliefs. If any information provided above is found incorrect/false application may be summarily rejected without giving any reason.

Signature of the Applicant with date and Stamp

Name:

Mobile No.:

Email ID:

Annexure –B

A. Leaders Category Awards

1. India Pharma Leader Award

Criterion of Selection with weightage

a. Average of Sales Turn over for the last three years – **25 marks**
b. Average of the Exports Turn over for the last three years – **25 marks**
c. Average of the Sales of NLEMs vis-à-vis total sales for the last three years - **20 marks**
d. No of products – Protocol and Non-protocol COVID drugs produced for the last two FYs – **10 marks**
e. Average of the Expenditures on R&D vis-à-vis total sales turn over for the last three years – **10 marks**

India Pharma Leader Award				
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1.Pharmaceuticals 2. Bio-Pharma			
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto		
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**	
4. ISO 13485 certification details (IF Applicable)		**Validity**		
5. State Manufacturing Licence (If Applicable)		**Validity**		
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**		
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**		
8. Start-up Registered with DPIIT		**Validity**		
9. Registered Office Address including District and State				
10. Corporate Office Address including District and State				
11. Website				
12. Criteria	**2018-19**	**2019-20**	**2020-21**	**Remark**
Sales Figures (INR Cr) (25 Marks)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic				
Export **(25 Marks)**				Extracts from the audited balance sheet and profit & loss; OR

				Certificate by the statutory auditor
Sales Figures (INR Cr) of NLEMS (vis-à-vis total sales) (20 Marks)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic				
Export				
No. of products (protocol COVID drugs produced for the last two financial Years (10 Marks)				(Formulation drug list having the drop-down selection of Protocol and non-protocol)
Expenditures on R&D (vis-à-vis total sales turn over for the last three years (10 Marks) (INR Cr)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Total Marks				

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ -Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Sales Annual turnover (Domestic and Export separately) (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Export Annual turnover (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Sales of NLEMS Drugs ((INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor NLEM list of drugs to be selectable in drop-down
No. of products (protocol COVID drugs produced for the last two financial Years	Yes/No		Manufacturing licence to be provided issued by CDSCO/State licencing Authority.
Expenditures on R&D (vis-à-vis total sales turn over)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor

2. India Medical Devices Leader Award

Criterion of Selection with weightage

a. Average of Sales Turn over for the last three years – **25 marks**
b. Average of the Exports Turn over for the last three years – **25 marks**
c. No of products – medical devices / equipment for COVID management produced for the last two FYs – **20 marks**
d. No of Medical Devices / Equipment (other than the notified MDs) already registered with the CDSCO till 31.12.2021 (during the voluntary registration period) – **20 marks**
e. Average of the Expenditures on R&D vis-à-vis total sales turn over for the last three years – **10 marks**

India Medical Devices Leader Award				
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1. Medical Devices			
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto		
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**	
4. ISO 13485 certification details (IF Applicable)		**Validity**		
5. State Manufacturing Licence (If Applicable)		**Validity**		
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**		
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**		
8. Start-up Registered with DPIIT		**Validity**		
9. Registered Office Address including District and State				
10. Corporate Office Address including District and State				
11. Website				
12. Criteria	**2018-19**	**2019-20**	**2020-21**	**Remark**
Sales Turnover for the last three years (INR Cr) (25 Marks)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic				
Exports (25 Marks)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor

No. of Products-medical devices/equipment for COVID management produced for the last two FYs (20 Marks)	-			Medical Devices used in COVID-19 drop-down list to be selectable
No. of Medical Devices/Equipment (other than the notified MDs) already registered with the CDSCO till 31.12.2021 (during the voluntary registration period) (20 Marks)				Registration Certificates to be uploaded
Average of the Expenditure on R&D vis-à-vis total sales turn over for the last three years (10 marks) (INR Cr)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Total Marks				

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ -Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Sales Annual turnover (Domestic and Export separately) (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Export Annual turnover (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
No. of products – medical devices / equipment for COVID management produced for the last two financial Years	Yes/No		Manufacturing licence to be provided issued by CDSCO/State licencing Authority for each product. (Medical Devices used in COVID-19 drop-down list to be selectable)
No. of Medical Devices/Equipment (other than the notified MDs) already registered with the CDSCO till 31.12.2021	Yes/No		CDSCO Registration Certificates to be uploaded.
Expenditures on R&D for Medical Devices (vis-à-vis total sales turn over)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor

B. Company of the year Awards

1. India Pharma Bulk Drug company of the year

Criterion of Selection with weightage

a. % Increase in Sales Turn over vis-à-vis last year– **25 marks**
b. % of sales of APIs for manufacture of NLEM medicines– **25 marks**
c. % sales of APIs related to production of COVID drugs (Protocol and non-protocol) – **20 marks**
d. Number of APIs related to COVID management produced in FY 20-21 - **20 marks**
e. % Increase in R&D Expenditure on Bulk drugs vis-à-vis last year – **10 marks**

India Pharma Bulk Drug Company of the year			
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1.Pharmaceuticals 2. Bio-Pharma		
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto	
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**
4. ISO 13485 certification details (IF Applicable)		**Validity**	
5. State Manufacturing Licence (If Applicable)		**Validity**	
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**	
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**	
8. Start-up Registered with DPIIT		**Validity**	
9. Registered Office Address including District and State			
10. Corporate Office Address including District and State			
11. Website			
12. Criteria	**2019-20**	**2020-21**	**Remark**
Sales turn over (INR Cr) (25 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic			
Export			
Sale of APIs for manufacture of NLEM medicines Export (25 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor (NELM Drugs/Formulation to be selected by drop down)
Sale of APIs related to production of COVID drugs (Protocol and non-protocol) (20 Marks)			Extracts from the audited balance sheet and profit & loss; OR

Domestic			Certificate by the statutory auditor (Formulation drug list having the drop-down selection of Protocol and non-protocol)
Export			
Number of APIs related to COVID management produced (20 Marks)			(Formulation drop-down list to selectable for Protocol and non-protocol drugs)
R&D Expenditure on Bulk drugs (10 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Total Marks			

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ -Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Sales Annual turnover (Domestic and Export vis-à-vis last two year) (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Sale of APIs for manufacture of NLEM medicines of last two year (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor (Formulation list of NLEM drugs drop down for selection)
Sales of APIs related to production of COVID drugs (Protocol and non-protocol) (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor (Formulation drug list having the drop-down selection for Protocol and non-protocol)
Number of APIs related to COVID management produced in FY 20-21	Yes/No		Manufacturing licence to be provided issued by CDSCO/State licencing Authority.
Expenditures on R&D for Bulk Drugs (vis-à-vis last year)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor

2. India Formulation Company of the year

Criterion of Selection with weightage

a. % Increase in Sales Turn over vis-à-vis last year– **25 marks**
b. % of sales of of NLEM medicines vis-à-vis total sales – **25 marks**
c. % sales of Medicines for COVID management (Protocol and non-protocol) – **20 marks**
d. Number of Medicines for COVID management produced in FY 20-21 - **20 marks**
e. % Increase in R&D Expenditure on formulation drugs drugs vis-à-vis last year – **10 marks**

India Formulation Company of the year			
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1.Pharmaceuticals 2. Bio-Pharma		
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto	
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**
4. ISO 13485 certification details (IF Applicable)		**Validity**	
5. State Manufacturing Licence (If Applicable)		**Validity**	
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**	
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**	
8. Start-up Registered with DPIIT		**Validity**	
9. Registered Office Address including District and State			
10. Corporate Office Address including District and State			
11. Website			
12. Criteria	**2019-20**	**2020-21**	**Remark**
Sales Turn over (25 marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic			
Export			
Sale of NLEM medicines vis-à-vis total sales (25 marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor NELM drugs to be selected by drop-down
Sale of Medicines for COVID management (Protocol and non-protocol) (20 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor (Formulation drug list having the

			drop-down selection of Protocol and non-protocol)
Domestic			
Export			
Number of Medicines for COVID management produced FY 2020-21 (20 Marks)			Formulation drug list having the drop-down selection of Protocol and non-protocol
R&D Expenditure on formulation drugs (10 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Total Marks			

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ -Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Sales Annual turnover (Domestic and Export separately) (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Export Annual turnover (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Sales of NLEMS Drugs ((INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor NELM drugs drop-down to be selectable
Number of Medicines for COVID management produced FY 2020-21	Yes/No		Manufacturing licence to be provided issued by CDSCO/State licencing Authority. (Formulation drug list having the drop-down selection of Protocol and non-protocol)
Expenditures on R&D for formulation drugs (vis-à-vis total sales turn over)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor

3. India Medical Device company of the year

Criterion of Selection with weightage

a. % Increase in Sales Turn over vis-à-vis last year– **25 marks**
b. % of export out of total sales in the FY 20-21– **25 marks**
c. % of sales of Medical Devices for COVID management produced out of total sales in FY 20-21– **20 marks**
d. Number of Medical Devices for COVID management produced in FY 20-21 - **20 marks**
e. % Increase in R&D Expenditure on Medical Devices vis-à-vis last year – **10 marks**

India Medical Device Company of the year			
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1. Medical Devices		
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto	
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**
4. ISO 13485 certification details (IF Applicable)		**Validity**	
5. State Manufacturing Licence (If Applicable)		**Validity**	
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**	
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**	
8. Start-up Registered with DPIIT		**Validity**	
9. Registered Office Address including District and State			
10. Corporate Office Address including District and State			
11. Website			
12. Criteria	**2019-20**	**2020-21**	**Remark**
Sales Turn over (25 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic			
Export (25 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Sale of Medical Devices for COVID management produced out of total sales (20 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor

			(Medical Devices used in COVID-19 list to be selectable in drop-down)
Domestic			
Export			
Number of Medical Devices for COVID management produced (20 Marks)			Drop down list to be select able
R&D Expenditure on Medical Devices (10 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Total Marks			

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ -Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Sales Annual turnover (Domestic and Export separately) (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Export Annual turnover for Medical Devices (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Sales of Medical Devices for COVID management produced in FY 20-21 (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor list of Medical Devices to be selectable in drop-down
Number of Medical Devices for COVID management produced in FY 20-21	Yes/No		Manufacturing licence to be provided issued by CDSCO/State licencing Authority. Drop down list of Medical Devices to be selectable
Expenditures on R&D for Medical Devices (vis-à-vis total sales turn over)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor

C. MSME Category Awards

1. India Pharma / API MSME of the year

Criterion of Selection with weightage

f. % Increase in Sales Turn over vis-à-vis last year– **25 marks**
g. % of sales of of NLEM APIs / medicines vis-à-vis total sales – **25 marks**
h. % sales of APIs / Medicines for COVID management (Protocol and non-protocol) – **20 marks**
i. Number of APIs / Medicines for COVID management produced in FY 20-21 - **20 marks**
j. Financial assistance received from MSME schemes of Govt of India / State Government – **10 marks**

India Pharma/ API MSME of the year			
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1.Pharmaceuticals 2. Bio-Pharma 3. MSME		
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto	
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**
4. ISO 13485 certification details (IF Applicable)		**Validity**	
5. State Manufacturing Licence (If Applicable)		**Validity**	
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**	
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**	
8. Start-up Registered with DPIIT		**Validity**	
9. Registered Office Address including District and State			
10. Corporate Office Address including District and State			
11. Website			

12. Criteria	**2019-20**	**2020-21**	**Remark**
Sales Turn over (25 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic			
Export			
Sales NLEM APIs/ Medicines vis-à-vis total sales (25 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor NLEM formulation/drug list be drop-down selectable
Domestic			
Export			

Sales of APIs/Medicines for COVID management (Protocol and non-protocol) (20 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor (Formulation drug list having the drop-down selection of Protocol and non-protocol)
Domestic			
Export			
Number of APIs/Medicines for COVID management produced FY 20-21 (20 Marks)			(Formulation drug list having the drop-down selection of Protocol and non-protocol))
Financial assistance received from MSME schemes of Govt of India / State Government (10 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Total Marks			

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ -Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Sales Annual turnover of APIs/Medicines (Domestic and Export separately) (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Sales of NLEMS Drugs APIs/Medicines ((INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Sales of APIs/Medicines for COVID management (Protocol and non-protocol) ((INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Number of APIs/Medicines for COVID management produced FY 20-21	Yes/No		Drop-down list of protocol and non-Protocol be selectable.
Financial assistance received from MSME schemes of Govt of India / State Government	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor

2. India Medical Device MSME of the year

Criterion of Selection with weightage

e. % Increase in Sales Turn over vis-à-vis last year– **30 marks**
f. % sales of Medical Devices / Equipment for COVID management (Protocol and non-protocol) – **30 marks**
g. Number of Medical Devices / Equipment for COVID management produced in FY 20-21 - **30 marks**
h. Financial assistance received from MSME schemes of Govt of India / State Government – **10 marks**

India Medical Device MSME of the year			
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1. Medical Devices 2. MSME		
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto	
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**
4. ISO 13485 certification details (IF Applicable)		**Validity**	
5. State Manufacturing Licence (If Applicable)		**Validity**	
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**	
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**	
8. Start-up Registered with DPIIT		**Validity**	
9. Registered Office Address including District and State			
10. Corporate Office Address including District and State			
11. Website			
12. Criteria	**2019-20**	**2020-21**	**Remark**
Sales Turn over (30 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic			
Export			
Sale of Medical Devices / Equipment for COVID management (Protocol and non-protocol (30 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic			
Export			
Number of Medical Devices / Equipment for COVID management produced in FY 20-21 (30 Marks)			(Drop down list to be selectable)

Financial assistance received from MSME schemes of Govt of India / State Government (10 Marks)			Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Total Marks			

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ - Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Sales Annual turnover (Domestic and Export separately) (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Sale of Medical Devices / Equipment for COVID management (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor Drop-down list of COVID Management
Number of Medical Devices / Equipment for COVID management produced in FY 20-21 ((INR Cr)	Yes/No		Drop-down list of COVID Management Medical Devices
Financial assistance received from MSME schemes of Govt of India / State Government	Yes/No		Applicable certificates to be uploaded

D. Start-up category

1. India Pharma Start-up of the year

Criterion of Selection with weightage

a. Cumulative number of the pharmaceutical products produced by the Start-up – **25 marks**
b. Average of the sales of the pharmaceutical products during last three years – **25 marks**
c. cumulative Number of Pharmaceutical products registered with GeM portal by Start-up firm in last three years – **20 marks**
d. Cumulative Number of Pharmaceutical products approved by CDSCO/ AERB/ Regulatory approval of USA, UK, Australia, Japan, Canada, European Union (CE) in last three years .- **20 marks**
e. Number of the new pharmaceutical products / new processes, used by the Start-up firms for the last three years – **10 marks**

India Pharma Start-up of the year				
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1. Start-up			
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto		
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**	
4. ISO 13485 certification details (IF Applicable)		**Validity**		
5. State Manufacturing Licence (If Applicable)		**Validity**		
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**		
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**		
8. Start-up Registered with DPIIT		**Validity**		
9. Registered Office Address including District and State				
10. Corporate Office Address including District and State				
11. Website				
12. Criteria	**2018-19**	**2019-20**	**2020-21**	**Remark**
Cumulative number of the pharmaceutical products produced by the Start-up (25 marks)				Manufacturing licence to be provided issued by CDSCO/State licencing Authority.
Sales of the pharmaceutical products (25 Marks)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor

Cumulative Number of Pharmaceutical products registered with GeM portal by Start-up firm (20 Marks)				Manufacturing licence to be provided issued by CDSCO/State licencing Authority/ applicable certificates to be uploaded
Cumulative Number of Pharmaceutical products approved by CDSCO/ AERB/ Regulatory approval of USA, UK, Australia, Japan, Canada, European Union (CE) (20 Marks)				Manufacturing licence to be provided issued by CDSCO/State licencing Authority/ applicable certificates to be uploaded
Number of the new pharmaceutical products / new processes, used by the Start-up firms (10 marks)				Manufacturing licence to be provided issued by CDSCO/State licencing Authority/ applicable certificates to be uploaded
Total Marks				

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ -Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Cumulative number of the pharmaceutical products produced by the Start-up	Yes/No		Manufacturing licence to be provided issued by CDSCO/State licencing Authority/ applicable certificates to be uploaded
Sales of the pharmaceutical products (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Cumulative Number of Pharmaceutical products registered with GeM portal by Start-up firm ((INR Cr)	Yes/No		Manufacturing licence to be provided issued by CDSCO/State licencing Authority/ applicable certificates to be uploaded
Cumulative Number of Pharmaceutical products approved by CDSCO/ AERB/ Regulatory approval of USA, UK, Australia, Japan, Canada, European Union (CE)	Yes/No		Manufacturing licence to be provided issued by CDSCO/State licencing Authority/ Applicable certificate to be uploaded
Number of the new pharmaceutical products / new processes, used by the Start-up firms	Yes/No		Manufacturing licence to be provided issued by CDSCO/State licencing Authority/ applicable certificates to be uploaded

2. **India Medical Device Start-up of the year**

Criterion of Selection with weightage

a. Cumulative number of the Medical Devices / Equipment produced by the Start-up – **25 marks**
b. Average of the sales of the Medical Devices / Equipment during last three years – **25 marks**
c. cumulative Number of Medical Devices / Equipment registered with GeM portal by Start-up firm in last three years – **20 marks**
d. Cumulative Number of Medical Devices / Equipment approved by CDSCO/ AERB/ Regulatory approval of USA, UK, Australia, Japan, Canada, European Union (CE) in last three years .- **20 marks**
e. Number of the new Medical Devices / Equipment / new processes, used by the Start-up firms for the last three years – **10 marks**

India Medical Devices Start-up of the year				
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1. Start-up			
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto		
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**	
4. ISO 13485 certification details (IF Applicable)		**Validity**		
5. State Manufacturing Licence (If Applicable)		**Validity**		
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**		
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**		
8. Start-up Registered with DPIIT		**Validity**		
9. Registered Office Address including District and State				
10. Corporate Office Address including District and State				
11. Website				
12. Criteria	**2018-19**	**2019-20**	**2020-21**	**Remark**
Cumulative number of the Medical Devices / Equipment produced by the Start-up (25 marks)				Manufacturing licence to be provided issued by CDSCO/State licencing Authority/ applicable certificates to be uploaded
Sales of the Medical Devices / Equipment products (25 Marks)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor

Cumulative Number of Medical Devices / Equipment registered with GeM portal by Start-up firm (20 Marks)				Manufacturing licence to be provided issued by CDSCO/ State licencing Authority/ applicable certificates to be uploaded
Cumulative Number of Medical Devices / Equipment approved by CDSCO/ AERB/ Regulatory approval of USA, UK, Australia, Japan, Canada, European Union (CE) (20 Marks)				Manufacturing licence to be provided issued by CDSCO/ State licencing Authority/ applicable certificates to be uploaded
Number of the new Medical Devices / Equipment / new processes, used by the Start-up firms (10 marks)				Manufacturing licence to be provided issued by CDSCO/ State licencing Authority/ applicable certificates to be uploaded
Total Marks				

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ - Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Cumulative number of the Medical Devices / Equipment produced by the Start-up	Yes/No		Manufacturing licence to be provided issued by CDSCO/ State licencing Authority/ applicable certificates to be uploaded
Sales of the Medical Devices / Equipment products (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Cumulative Number of Medical Devices / Equipment registered with GeM portal by Start-up firm ((INR Cr)	Yes/No		Manufacturing licence to be provided issued by CDSCO/ State licencing Authority/ applicable certificates to be uploaded
Cumulative Number of Medical Devices / Equipment approved by CDSCO/ AERB/ Regulatory approval of USA, UK, Australia, Japan, Canada, European Union (CE)	Yes/No		Manufacturing licence to be provided issued by CDSCO/State licencing Authority.
Number of the new Medical Devices / Equipment / new processes, used by the Start-up firms	Yes/No		Manufacturing licence to be provided issued by CDSCO/ State licencing Authority/ applicable certificates to be uploaded

E. Innovation Category

1. India Pharma Innovation of the year

Criterion of Selection with weightage

a. Number of the patents filed for the last three years – **25 marks**
b. Number of product patents granted during the last three years - **(25 Marks)**
c. Average sales of the commercialized above patent products during the last three years – **25 marks**
d. % sales of commercialized patent products related to NLEMs – **25 marks**

India Pharma Innovation of the year				
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1.Pharmaceuticals 2. Bio-Pharma 3. Start-up 4. MSME			
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto		
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**	
4. ISO 13485 certification details (IF Applicable)		**Validity**		
5. State Manufacturing Licence (If Applicable)		**Validity**		
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**		
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**		
8. Start-up Registered with DPIIT		**Validity**		
9. Registered Office Address including District and State				
10. Corporate Office Address including District and State				
11. Website				

12. Criteria	**2018-19**	**2019-20**	**2020-21**	**Remark**
Number of the patents filed (25 Marks)				Patent filed application to be upload for drug.
Number of product patents granted (25 Marks)				Patent certificate to be uploaded
Sales of the commercialized above patent products (25 Marks)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic				
Export				

Commercialized patent products related to NLEMs (25 Marks)		NLEM drop down list to be selectable.
Total Marks		

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ - Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Number of the patents filed	Yes/No		Patent filed application to be upload for drug
Number of product patents granted	Yes/No		Patent certificate to be uploaded
Sales of the commercialized above patent products (Export and Domestic) (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Commercialized patent products related to NLEMs	Yes/No		NLEM drop down list to be selectable.

2. **India Medical Device Innovation of the year**

Criterion of Selection with weightage

a. Number of the patents related to the medical devices filed for the last three years – **25 marks**
b. Number of product patents related to medical devices granted during the last three years - **(25 Marks)**
c. Average sales of the commercialized above patent products during the last three years – **25 marks**
d. % sales of commercialized patent products related to COVID management– **25 marks**

India Medical Device Innovation of the year				
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1. Medical Devices 2. Start-up 3. MSME			
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto		
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**	
4. ISO 13485 certification details (IF Applicable)		**Validity**		
5. State Manufacturing Licence (If Applicable)		**Validity**		
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**		
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**		
8. Start-up Registered with DPIIT		**Validity**		
9. Registered Office Address including District and State				
10. Corporate Office Address including District and State				
11. Website				
12. Criteria	**2018-19**	**2019-20**	**2020-21**	**Remark**
Number of the patents related to the medical devices filed (25 Marks)				Patent applications to be uploaded
Number of product patents related to medical devices granted (25 Marks)				Patent certificate to be uploaded
Sales of the commercialized above patent products (25 Marks)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Domestic				
Export				
Sale of Commercialized patent products related to COVID management (25 Marks)				Extracts from the audited balance sheet and profit & loss;

				OR Certificate by the statutory auditor
Total Marks				

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ - Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Number of the patents related to the medical devices filed	Yes/No		Patent applications to be uploaded
Number of product patents related to medical devices granted	Yes/No		Patent certificate to be uploaded
Sales of the commercialized above patent products (Domestic and Export) (INR Cr)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
Sale of Commercialized patent products related to COVID management	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor.

F. CSR Category

India Pharma CSR company of the Year Award:

Criterion of Selection with weightage

f. Total expenditure incurred on these activities for the last three years **– 20 marks**
g. % of expenditure incurred towards improvement of public system such as public healthcare system, public educational institutions, etc **– 20 marks**
h. % of expenditure incurred on skill upgradation - **– 20 marks**
i. No of Districts covered under the CSR Programme for the last three years **– 20 marks**
j. No of Aspirational Districts covered under the CSR programme for the last three years **– 20 marks**

India Pharma CSR Company of the Year Award				
1. Brief Profile of Business (Give brief in the box and attach detail profile)	1.Pharmaceuticals 2. Bio-Pharma 3. Start-up 4. MSME			
2. Date of Incorporation		Provide copy of certificate of incorporation with Memorandum and Article of Association and the validity upto		
3. Business Registrations (Please attach copy of certificate)	**PAN**		**CIN**	
4. ISO 13485 certification details (IF Applicable)		**Validity**		
5. State Manufacturing Licence (If Applicable)		**Validity**		
6. CDSCO Manufacturing Licence (If Applicable)		**Validity**		
7. MSME Registration number/ Udhyog Aadhar issued by MSME. (If Applicable)		**Validity**		
8. Start-up Registered with DPIIT		**Validity**		
9. Registered Office Address including District and State				
10. Corporate Office Address including District and State				
11. Website				
12. Criteria	**2018-19**	**2019-20**	**2020-21**	**Remark**
Total expenditure incurred on CSR activities (20 Marks)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
% of Expenditure incurred towards improvement of public system such as public healthcare system, public educational institutions, etc (20 marks)				Extracts from the audited balance sheet and profit & loss; OR

				Certificate by the statutory auditor
% of Expenditure incurred on skill Upgradation (20 marks)				Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
No. of Districts covered under the CSR Programmed for the last three years (20 Marks)				
No. of Aspirational Districts covered under the CSR programme (20 Marks)				
Total Marks				

13. Key Information (If Applicable)	**Whether Information Provided**	**Details**	**Remarks**
Registration certificate of the Agency	Yes/No		Certificate of incorporation/ Partnership or Trust deed/ - Certificate of commencement of business (if applicable)/ Udhyog Aadhar issued by MSME.
Total expenditure incurred on CSR activities (20 Marks)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
% of Expenditure incurred towards improvement of public system such as public healthcare system, public educational institutions, etc (20 marks)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
% of Expenditure incurred on skill Upgradation (20 marks)	Yes/No		Extracts from the audited balance sheet and profit & loss; OR Certificate by the statutory auditor
No. of Districts covered under the CSR Programmed for the last three years (20 Marks)	Yes/No		Relevant documents to be uploaded.
No. of Aspirational Districts covered under the CSR programme (20 Marks)	Yes/No		Relevant documents to be uploaded.